Digest Network Come funziona
Network
/
Società
OS
Non verificato

OS Therapies, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieOncologiaSalute

14 comunicati stampa

Guarda tutti i comunicati
13/03/2025
Eventi
Fiere
Industria
Scienza
Medicina - Varie
Biotecnologia
Sanità
Salute
Farmaceutica
Oncologia
OS Therapies Awarded OST-HER2 Clinical Trial Data Presentation at MIB Agents FACTOR Osteosarcoma Conference
Fonte
OS Therapies, Inc.
Emittente
Business Wire
1.00
0
11/03/2025
Eventi
Industria
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
OS Therapies Schedules United Kingdom’s Medicines and Healthcare products Regulatory Agency's (MHRA) Scientific Advice Meeting in the Third Quarter of 2025 for Review of its OST-HER2 Immunotherapy Candidate for Osteosarcoma
Fonte
OS Therapies, Inc.
Emittente
Business Wire
1.00
0
24/02/2025
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Industria
OS Therapies Forms Subsidiary OS Drug Conjugates and Initiates Review of Strategic Options for its tunable ADC & Drug Conjugates Platforms
Fonte
OS Therapies, Inc.
Emittente
Business Wire
1.00
0
20/02/2025
Industria
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
OS Therapies Receives Patent Notice of Allowance from U.S. Patent & Trademark Office Covering Commercial Manufacturing of OST-HER2
Fonte
OS Therapies, Inc.
Emittente
Business Wire
1.00
0
14/02/2025
Oncologia
Salute
Igiene alimentare
Sanità
Medicina - Varie
Farmaceutica
Biotecnologia
Mercato del lavoro
Industria
OS Therapies Initiates Commercial-ready Manufacturing of OST-HER2 to Support Anticipated Biologics Licensing Authorization (BLA) Filing
Fonte
OS Therapies, Inc.
Emittente
Business Wire
1.00
0
04/02/2025
Biotecnologia
Igiene alimentare
Salute
Sanità
Farmaceutica
Oncologia
Scienza
Veterinaria
Medicina - Varie
Industria
OS Therapies Provides Corporate Update
Fonte
OS Therapies, Inc.
Emittente
Business Wire
1.00
0
15/01/2025
Analisi di mercato
Industria
Scienza
Biotecnologia
Farmaceutica
Oncologia
Sanità
Salute
Medicina - Varie
OS Therapies Announces Phase 2b Clinical Trial of OST-HER2 Achieves Primary Endpoint with Statistical Significance in the Prevention of Recurrent, Fully Resected, Lung Metastatic Osteosarcoma
Fonte
OS Therapies, Inc.
Emittente
Business Wire
1.00
0
15/01/2025
Analisi di mercato
Industria
Scienza
Biotecnologia
Farmaceutica
Oncologia
Sanità
Salute
Medicina - Varie
OS Therapies Announces Phase 2b Clinical Trial of OST-HER2 Achieves Primary Endpoint with Statistical Significance in the Prevention of Recurrent, Fully Resected, Lung Metastatic Osteosarcoma
Fonte
OS Therapies, Inc.
Emittente
Business Wire
1.00
0
02/01/2025
Eventi
Fiere
Oncologia
Salute
Scienza
Farmaceutica
Biotecnologia
OS Therapies to Attend the 43rd Annual J.P. Morgan Healthcare Conference
Fonte
OS Therapies, Inc.
Emittente
Business Wire
1.00
0
31/12/2025
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
OS Therapies Announces Closing of $6 Million Private Placement
Fonte
OS Therapies, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0